Is Victoza actually 'budget Ozempic'? What the data says

What did @icravethatmineral actually say?

The creator went to her GP hoping to get a dietitian referral and ADHD medication, and left instead with a prescription for Victoza (liraglutide) for obesity. She calls it "mommy's generic Ozempic" and "budget Ozempic," frames the prescription as a substitution for nutrition care she couldn't afford, and films herself injecting on camera, including skipping the alcohol swab initially and storing used needles in an empty Diet Coke can. She also mentions having no PCOS after testing, having lost 31 pounds already, and notes she's on the starting dose of 0.6 mg, titrating up gradually per instructions.

The video is candid, unscripted, and clearly not meant as medical advice. She says so herself: "don't follow my instructions, I'm just showing you my experience." That disclaimer matters for context, but the platform doesn't care about disclaimers. Twenty-three thousand people watched this. So let's work through what she got right and what needs correcting.

Does the science back this up?

Liraglutide works. That part is solid. But calling it "budget Ozempic" or "generic Ozempic" misrepresents what it is, and the distinction is not trivial.

Liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Wegovy) are both GLP-1 receptor agonists, but they are different molecules with different dosing schedules, efficacy profiles, and approved indications. Liraglutide requires daily injections; semaglutide is once weekly. The SCALE Obesity trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed liraglutide 3.0 mg produced about 8 percent mean body weight loss over 56 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg produced roughly 15 percent mean body weight loss. These are not equivalent drugs. Liraglutide is also not a generic of semaglutide. Victoza is brand-name liraglutide, not a generic of anything currently on the U.S. market.

The gradual titration she describes, starting at 0.6 mg and increasing, reflects the actual FDA-approved protocol for liraglutide and is medically appropriate to reduce gastrointestinal side effects. That part checks out.

What did they get wrong (or right)?

She got the titration right. She got the injection site (abdomen) right. She got the needle disposal wrong, and she mislabeled the drug in a way that will mislead a lot of viewers.

The Diet Coke can needle disposal is genuinely dangerous. The FDA is explicit: used sharps go in an FDA-cleared sharps container, or an approved alternative like a heavy-duty plastic laundry detergent bottle with a screw-top lid. A soda can has a opening that exposes the needle and can injure anyone handling the trash, including sanitation workers. This is not a minor procedural quibble. Needlestick injuries are a real occupational hazard and a real infection risk.

The "budget Ozempic" and "generic Ozempic" framing is the bigger misinformation problem. Liraglutide is not a generic version of semaglutide. They share a drug class, not a molecule. Viewers who hear "generic Ozempic" may assume equivalent weight-loss outcomes, which the data does not support. They might also assume interchangeability with compounded semaglutide products circulating online, which compounds the confusion in an already chaotic GLP-1 market.

What she got right: her frustration about dietitian access is legitimate. Research consistently shows that insurance coverage for medical nutrition therapy is limited. A 2022 analysis in the Journal of the Academy of Nutrition and Dietetics (Rozga et al.) found significant coverage gaps for dietitian services outside diabetes-specific diagnoses. Her doctor's pivot to medication over nutritional support reflects a real, systemic problem, not a personal failing.

What should you actually know?

If you are watching this video and thinking about liraglutide or any GLP-1 medication, here is what actually matters.

• Victoza (liraglutide) is FDA-approved for type 2 diabetes. Saxenda is the higher-dose version approved specifically for weight management. They are the same molecule, different approvals and doses. Neither is a generic of semaglutide.
• Sharps must go in an approved sharps container. Full stop. Most pharmacies sell them for a few dollars. Some offer free disposal programs. The FDA's Safe Sharps Disposal guidance is publicly available at fda.gov.
• GLP-1 medications prescribed for obesity should ideally be paired with behavioral and nutritional support. The SCALE trial used lifestyle counseling alongside liraglutide. The medication is more effective with that support, not instead of it.
• If your insurance denied dietitian coverage, you can appeal. The denial is not always final. A primary care physician or an endocrinologist can write a medical necessity letter, especially if there is a metabolic diagnosis in your chart.
• The creator mentioned no PCOS diagnosis, which is relevant. Unexplained weight resistance despite dieting does warrant metabolic workup, and her doctor ordering one was appropriate care.

Should you watch more videos like this?

Patient experience content has real value. Seeing someone actually go through injection technique, even imperfectly, normalizes treatment and reduces shame. The creator is not pretending to be a doctor. The problem is that platforms do not deliver context alongside the video. "Budget Ozempic" becomes a search term. The Diet Coke can becomes a tutorial. Twenty-three thousand viewers process this without a pharmacist in the room. That gap is where harm happens, not from bad intent, but from missing information at scale.